Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6411 posts found.

j

Valeant’s outgoing boss tells Senate committee he “regrets” drug price rises

April 28, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Senate, Valeant, admits, aggressive, committee, drug price, pearson, rises

Outgoing Valeant (NYSE: VRX) boss, Michael Pearson, expressed regret at the way his company conducted operations to a US Senate …
News
pfizer_finland_hq

Pfizer to pay $784.6 million fine due to Wyeth Medicaid fraud

April 28, 2016 Medical Communications, Sales and Marketing False Claims Act, Medicaid, Pfizer, US, Wyeth, department, fraud, insurer, justice

Pfizer has agreed to pay $784.6 million in a settlement with the US Department of Justice, relating to false and …
News
brexit

Remaining in the EU is vital for UK’s cancer research strength, say leading oncologists

April 27, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, EU, Europe, UK, brexit, britain, cancer research, cede, exit, implications, negative, oncology, pharma

Leading UK oncologists have written an article in the May issue of The Lancet, strongly urging Britain to remain in …
News
joseph_papa

Valeant names Joseph Papa as new chief executive officer

April 25, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Chairman, Valeant, joseph papa, new, new ceo, papa, pearson

Valeant Pharmaceuticals has announced that Joseph C. Papa will succeed Michael Pearson as chairman and chief executive officer of the …
Appointment
stocks2

Valeant receives further default notices due to its delayed 10-K filing

April 25, 2016 Medical Communications, Sales and Marketing Valeant, default, risk, trouble, worry

Valeant Pharmaceuticals has issued a statement detailing that they have received additional notices of default under indentures due to its …
News
astrazeneca_sign_sky

AstraZeneca to sequence genomes to develop new drugs

April 22, 2016 Medical Communications, Sales and Marketing AstraZeneca, Finland, Wellcome Trust, collaboration, genome, genomics, human longevity, institute for molecular medicine, sanger institute

AstraZeneca (LSE: AZN) has announced an integrated genomics initiative that aims to transform the drug discovery and development across is …
News
trials

AbbVie announces further industry and academic collaborations

April 22, 2016 Medical Communications, Research and Development AbbVie, collaboration, commercialisation, cytomx, partnership, research, university of chicago

AbbVie (NYSE: ABBV) has announced further collaborations that will see it partner with industry and academia to develop oncology candidates …
News
biogen_logo

Biogen Q1 profits rise boosted by Tecfidera sales

April 22, 2016 Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera

Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter …
News
lab

Novartis muscular drug fails in Phase III trials

April 22, 2016 Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III

A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …
News
actelion_logo

Actelion ups outlook for 2016, reports Q1 net income up 12%

April 22, 2016 Medical Communications, Sales and Marketing Actelion, Biotechnology, Q1 results, earnings, outlook

Swiss biotech company Actelion (VTX: ATLN) raised its outlook for 2016 and reported a 12% rise in first quarter net …
News
jevtana

A win for Sanofi on Jevtana after NICE reverses guidance

April 22, 2016 Medical Communications, Sales and Marketing Cancer Drugs Fund, Jevtana, NICE, Sanofi, recommendation, reversal

Prostate cancer treatment Jevtana (cabazitaxel), marketed by Sanofi (NYSE: SNY) has been recommended by NICE in its final guidance. The …
News
blue_jeans

Bluebird Bio gene therapy posts encouraging results in treatment of rare brain disease

April 21, 2016 Medical Communications, Research and Development Bluebird Bio, Phase II, gene therapy, lenti-d, paediatric, phase 2, phase 3, phase III, rare brain disease

Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …
News

PCI Pharma Services’ Ian Parsonage to Share Serialization Expertise at Global Track & Trace Conference

April 21, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ian parsonage, pci pharma, serialisation

Ian Parsonage, Senior Director of Global Serialization for leading pharmaceutical services provider PCI Pharma Services, will present at the Global …
News
Press release
novo_corp_hq2

Novo unveils new research grant to mark World Haemophilia Day

April 18, 2016 Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, grant, haemophilia, hero, world haemophilia day

Novo Nordisk has marked World Haemophilia Day 2016 with the announcement of a new research grant aimed at supporting and …
News
gavel

Roche sues Intas Pharma over patent dispute in India

April 18, 2016 Medical Communications, Sales and Marketing India, Roche, anaemia, chronic kidney, intas, intas pharmaceuticals, patent

Roche Pharmaceuticals is suing Indian-based Intas Pharmaceuticals, alleging that the company has infringed upon its patent rights to anaemia drug, …
News
The Gateway to Local Adoption Series

Latest content

Closing the immunisation gap: partnership working that delivered at scale

June 5, 2026

Phase 2 study explores imaging approach for interstitial lung disease

June 5, 2026

Laverock secures funding for gene-control platform development

June 4, 2026

LifeArc and Elpida partner to advance gene therapies for ultra-rare childhood diseases

June 3, 2026

Well Pharmacy and Alzheimer’s Society launch dementia partnership

June 2, 2026